据印度代购了解，c-MET既能够作为肺癌的原发致癌驱动基因,也是EGFR靶向治疗取得性耐药的缘由之一。c-MET抑止剂有下面这种方式。

ICN280结合吉非替尼吴一龙教授牵头的一项Ib期/II期临床研讨，目前报道了关于EGFR-TKI耐药的cMET+ 非小细胞肺癌患者，ICN280 400 mg，1天2次。结合吉非替尼治疗具有较好的耐受性，并表现出一定的临床疗效，假如是cMET高扩增表达的患者可能临床获益更大。

ICN280 combined with gefitinib in a Phase Ib /II clinical study led by Prof. Yilong Wu, is currently reported in patients with EGFR-TKI resistance in cMET+ non-small cell lung cancer, ICN280 400 mg, twice a day. Gefitinib combined with gefitinib was well tolerated and showed certain clinical efficacy. Patients with high amplified cMET expression may have greater clinical benefit.

据印度代购了解，ICN280结合吉非替尼在MET基因异常NSCLC中的疗效的实验中。II期研讨结果显现在83例入组肺癌患者中，66例(80%)曾承受EGFR-TKI单药或结合治疗。结果显现：

据印度代购了解，最常见的不良反响依次为低蛋白血症(29%)、四周性水肿(27%)、食欲减退(23%)。最常见的3级-4级不良反响为淀粉酶升高(7%)。

该研讨结果提示INC280治疗EGFR TKI 耐药后 cMET+ NSCLC患者平安有效。

The results of this study suggest that INC280 is safe and effective in cMET+ NSCLC patients with EGFR TKI resistance.